| Date Filed | Type | Description |
| 10/12/2023 |
8-K
| Quarterly results |
| 10/11/2023 |
8-K
| Quarterly results |
| 08/23/2023 |
SC 13D/A
| ORBIMED ADVISORS LLC reports a 13.5% stake in PMV Pharmaceuticals, Inc. |
| 08/09/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/09/2023 |
8-K
| Quarterly results |
| 08/08/2023 |
4
| Mack David Henry (President and CEO) has filed a Form 4 on PMV Pharmaceuticals, Inc.|
Txns:
| Exercised 85,500 options to buy
@ $0.53, valued at
$45.3k
|
|
| 07/07/2023 |
SC 13G/A
| BlackRock Inc. reports a 10.2% stake in PMV PHARMACEUTICALS, INC. |
| 06/12/2023 |
4
| Stelzer Laurie (Director) has filed a Form 4 on PMV Pharmaceuticals, Inc.|
Txns:
| Granted 21,500 options to buy
@ $5.59, valued at
$120.2k
|
|
| 06/12/2023 |
4
| LEVINE ARNOLD J (Director) has filed a Form 4 on PMV Pharmaceuticals, Inc.|
Txns:
| Granted 21,500 options to buy
@ $5.59, valued at
$120.2k
|
|
| 06/12/2023 |
4
| Heyman Richard A. (Director) has filed a Form 4 on PMV Pharmaceuticals, Inc.|
Txns:
| Granted 21,500 options to buy
@ $5.59, valued at
$120.2k
|
|
| 06/12/2023 |
4
| Gallagher Carol Giltner (Director) has filed a Form 4 on PMV Pharmaceuticals, Inc.|
Txns:
| Granted 21,500 options to buy
@ $5.59, valued at
$120.2k
Gifted 21,500 options to buy
@ $5.59, valued at
$120.2k
Gifted 21,500 options to buy
@ $5.59, valued at
$120.2k
|
|
| 06/12/2023 |
4
| FLOWERS KIRSTEN (Director) has filed a Form 4 on PMV Pharmaceuticals, Inc.|
Txns:
| Granted 21,500 options to buy
@ $5.59, valued at
$120.2k
|
|
| 06/12/2023 |
4
| BAUM CHARLES M (Director) has filed a Form 4 on PMV Pharmaceuticals, Inc.|
Txns:
| Granted 21,500 options to buy
@ $5.59, valued at
$120.2k
|
|
| 06/09/2023 |
8-K
| Submission of Matters to a Vote of Security Holders Interactive Data |
| 05/19/2023 |
SC 13G
| CITADEL ADVISORS LLC reports a 4.9% stake in PMV Pharmaceuticals, Inc. |
| 05/15/2023 |
4
| Jalota Deepika (Chief Development Officer) has filed a Form 4 on PMV Pharmaceuticals, Inc.|
Txns:
| Granted 125,000 options to buy
@ $5.7, valued at
$712.5k
|
|
| 05/15/2023 |
4
| Alland Leila (Chief Medical Officer) has filed a Form 4 on PMV Pharmaceuticals, Inc.|
Txns:
| Granted 100,000 options to buy
@ $5.7, valued at
$570k
|
|
| 05/15/2023 |
4
| Kung Winston (COO, CFO) has filed a Form 4 on PMV Pharmaceuticals, Inc.|
Txns:
| Granted 150,000 options to buy
@ $5.7, valued at
$855k
|
|
| 05/15/2023 |
4
| Mack David Henry (President and CEO) has filed a Form 4 on PMV Pharmaceuticals, Inc.|
Txns:
| Granted 330,000 options to buy
@ $5.7, valued at
$1.9M
|
|
| 05/10/2023 |
SC 13G/A
| STATE STREET CORP reports a 1.4% stake in EXIT FILING PMV PHARMACEUTICALS INC |
| 05/10/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 05/10/2023 |
8-K
| Quarterly results |
| 05/01/2023 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 04/28/2023 |
ARS
| Form ARS - Annual Report to Security Holders: |
| 04/28/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 04/28/2023 |
8-K
| Quarterly results |
| 04/28/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 03/01/2023 |
POS AM
| Form POS AM - Post-Effective amendments for registration statement: |
| 03/01/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
| 03/01/2023 |
8-K
| Quarterly results |
| 03/01/2023 |
POSASR
| Form POSASR - Post-effective Amendment to an automatic shelf registration statement: |
| 02/14/2023 |
SC 13G/A
| Boxer Capital, LLC reports a 6.9% stake in PMV Pharmaceuticals, Inc. |
| 02/14/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/14/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
|